Drugs / KYV-101
Trials 12 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT06152172 | Aug 2024 → Feb 2027 expected | anti-neutrophil cytoplasmic antibody-associated vasculitis, diffuse cutaneous systemic sclerosis, idiopathic inflammatory myopathy, lupus nephritis | David Porter | Active not recruiting | No outcome recorded |
| Phase 1 | NCT06298019 | Aug 2024 → Apr 2027 expected | dermatomyositis | Stanford University | Recruiting | No outcome recorded |
| Phase 1 | NCT06451159 | Jun 2024 → Feb 2026 overdue | multiple sclerosis | Bruce Cree | Active not recruiting | No outcome recorded |
| Phase 1 | NCT06138132 | Apr 2024 → Jun 2027 expected | primary progressive multiple sclerosis, secondary progressive multiple sclerosis | Stanford University | Recruiting | No outcome recorded |
| Phase 1/25 trials | ||||||
| Phase 1/2 | NCT06590545 | Jan 2025 → Jan 2027 expected | anti-neutrophil cytoplasmic antibody-associated vasculitis | David Simon | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT06475495 | Dec 2024 → Jun 2027 expected | rheumatoid arthritis | Charite University, Berlin, Germany | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT06400303 | Aug 2024 → Mar 2026 overdue | diffuse cutaneous systemic sclerosis | Kyverna Therapeutics | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT05938725 | Apr 2023 → Aug 2026 overdue | lupus nephritis | Kyverna Therapeutics | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT06342960 | Dec 2022 → Oct 2028 expected | lupus nephritis | Kyverna Therapeutics | Active not recruiting | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT06588491 | Sep 2024 → Jul 2026 overdue | classic stiff person syndrome | Kyverna Therapeutics | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06384976 | Sep 2024 → Apr 2027 expected | primary progressive multiple sclerosis, secondary progressive multiple sclerosis | Kyverna Therapeutics | Active not recruiting | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT06193889 | Aug 2024 → Sep 2027 expected | generalized myasthenia gravis | Kyverna Therapeutics | Recruiting | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KYV101 | “The purpose of this study is to assess the safety, tolerability, and clinical activity of KYV 101 (a fully-human anti-CD19 CAR T-cell therapy) in adult subjects with B...” NCT06152172 ↗13“This study aims to investigate the use of KYV101 (a fully human anti-CD19 CAR T cell therapy) in ANCA-IgG-positive AAV patients who are refractory to previous treatments.” NCT06590545 ↗ “Participants in the test-arm will receive a single dose of KYV-101 i.v., an autologous fully-human anti-CD19 CAR T-cell immunotherapy.” NCT06475495 ↗ “Dosing with KYV-101 CAR T cells” NCT06588491 ↗ |
| Known as | miv-cel | “KYV-101 (mivocabtagene autoleucel \[miv-cel\])), a fully human anti-CD19 CAR T-cell therapy” NCT06193889 ↗ |
| Known as | mivocabtagene autoleucel | “KYV-101 (mivocabtagene autoleucel \[miv-cel\])), a fully human anti-CD19 CAR T-cell therapy” NCT06193889 ↗ |
| Action | Deplete | “directly and specifically lyse target cells to effectively deplete B cells” NCT05938725 ↗ |
| Modality | Cell therapy | “KYV-101, a fully human anti-CD19 CAR T-cell therapy” NCT05938725 ↗ |
| Route | Intravenous | “will be administered IV as a single infusion” NCT06152172 ↗ |
| Target | CD19 | “KYV-101, a fully human anti-CD19 CAR T-cell therapy” NCT05938725 ↗ |